Higher population-based incidence rates of triple-negative breast cancer among young African-American women

Cancer

Volumn 117, Issue 12, 2011, Pages 2747-2753

  Amirikia, Kathryn C ^a   Mills, Paul ^b   Bush, Jason ^c   Newman, Lisa A ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CALIFORNIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED;

EID: 79958834872     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25862     Document Type: Article

References (31)

1. American Cancer Society. Breast Cancer Facts & Figures, 2009-2010. Atlanta, GA: American Cancer Society; 2010.
2. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792. (Pubitemid 41549890)
3. Anderson WF, Chatterjee N, Ershler WB, Brawley OW,. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002; 76: 27-36. (Pubitemid 35178626)
4. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 151: 716-726, W-236.
5. Parise CA, Bauer KR, Caggiano V,. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol. 2010; 76: 44-52.
6. Parise CA, Bauer KR, Brown MM, Caggiano V,. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009; 15: 593-602.
7. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V,. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 2008; 112: 737-747. (Pubitemid 351240567)
8. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V,. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007; 109: 1721-1728. (Pubitemid 46668532)
9. National Cancer Institute; Surveillance, Epidemiology and End Results Program. SEER*Stat software, version 6.5.2. Accessed December 1, 2009.
10. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684. (Pubitemid 41464706)
11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672. (Pubitemid 41464705)
12. Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006 [based on the November 2008 SEER data submission, posted to the SEER website, 2009]. Bethesda, MD: National Cancer Institute; 2009.
13. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110: 876-884. (Pubitemid 47257667)
14. Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer. 2008; 113: 608-615.
15. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009; 113: 357-370.
16. Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG,. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early stage breast cancer. Cancer. 2008; 113: 2565-2574.
17. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502. (Pubitemid 43854964)
18. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L,. Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Intern Med. 2009; 151: 727-737, W237-W242.
19. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009; 151: 738-747.
20. Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008; 111: 405-410.
21. Yang TJ, Yang Q, Haffty BG, Moran MS,. Prognosis for mammographically occult, early stage breast cancer patients treated with breast-conservation therapy. Int J Radiat Oncol Biol Phys. 2010; 76: 79-84.
22. Kojima Y, Tsunoda H,. Mammography and ultrasound features of triple-negative breast cancer [published online ahead of print October 23, 2010]. Breast Cancer. 2010.
23. Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA,. Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol. 2010; 20: 1111-1117.
24. Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G,. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 479-485.
25. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109: 123-139. (Pubitemid 351538762)
26. Palmer JR, Wise LA, Horton NJ, Adams-Campbell LL, Rosenberg L,. Dual effect of parity on breast cancer risk in African-American women. J Natl Cancer Inst. 2003; 95: 478-483. (Pubitemid 36432422)
27. Ursin G, Bernstein L, Wang Y, et al. Reproductive factors and risk of breast carcinoma in a study of white and African-American women. Cancer. 2004; 101: 353-362. (Pubitemid 38890840)
28. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009; 27: 4515-4521.
29. Bird PA, Hill AG, Houssami N,. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol. 2008; 15: 1983-1988.
30. Stark A, Kleer CG, Martin I, et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. 2010; 116: 4926-4932.
31. Fregene A, Newman LA,. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer. 2005; 103: 1540-1550. (Pubitemid 40490014)